The chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC), is being manufactured through AXIM’s contract manufacturer Eurofins Amatsigroup in Belgium. It will be used in AXIM’s upcoming clinical studies on cannabis as a treatment for chemotherapy-related symptoms. Symptoms that many chemotherapy patients experience include a weakened immune system, pain, nausea, vomiting, and diarrhea.
According to the Center for Disease Control and Prevention, about 650,000 cancer patients in the U.S. receive chemotherapy each year with an average cost of $100,000 per patient per year.
CBD-Based Chewing Gum
In the coming months, AXIM plans to conduct a bioequivalence study between its chewing gum with dronabinol and FDA-approved capsules containing dronabinol. The company intends to later provide evidence that the dronabinol chewing gum can serve as an alternative to orally ingested dronabinol for the treatment of symptoms associated with chemotherapy.
John Huemoeller II, the CEO of AXIM, states that their delivery mechanism allows products “to enter the body through the oral mucosa, bypassing the liver and allowing for greater bioavailability.”
“Through these studies, we want to show the bioequivalence of our dronabinol gum to already FDA-approved synthetic THC products so that we can offer it to chemotherapy patients through our proven and convenient delivery mechanism,” according to Huemoeller.